What is the typical dosage of Levetiracetam (Keppra) for seizure treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Levetiracetam (Keppra) Dosage for Seizure Treatment

The typical dosage of levetiracetam (Keppra) for seizure treatment in adults is 1000-3000 mg/day, given as twice-daily dosing, starting with 1000 mg/day (500 mg BID) and increasing by 1000 mg/day every 2 weeks as needed. 1

Adult Dosing (16 years and older)

  • Initial dose: 1000 mg/day divided as 500 mg twice daily 1
  • Titration: Increase by 1000 mg/day every 2 weeks as needed 1
  • Maintenance dose: 1000-3000 mg/day (typically 3000 mg/day for optimal efficacy) 1, 2
  • Maximum recommended dose: 3000 mg/day, although higher doses have been used in open-label studies 1

Pediatric Dosing

  • Children 4 to <16 years: Start with 20 mg/kg/day divided into two doses (10 mg/kg twice daily) 1
  • Titration: Increase by 20 mg/kg every 2 weeks 1
  • Target dose: 60 mg/kg/day (30 mg/kg twice daily) 1
  • For children ≤20 kg: Use oral solution 1
  • For children >20 kg: Can use either tablets or oral solution 1

Dosing for Specific Seizure Types

Partial Onset Seizures

  • Adults: 1000-3000 mg/day (500-1500 mg twice daily) 1
  • Children: 20-60 mg/kg/day (10-30 mg/kg twice daily) 1

Myoclonic Seizures (12 years and older)

  • Start with 1000 mg/day (500 mg twice daily) 1
  • Increase by 1000 mg/day every 2 weeks 1
  • Recommended dose: 3000 mg/day 1

Primary Generalized Tonic-Clonic Seizures

  • Adults: Same as partial onset seizures 1
  • Children 6 to <16 years: 20-60 mg/kg/day (10-30 mg/kg twice daily) 1

Status Epilepticus Dosing

  • For benzodiazepine-resistant status epilepticus: 30 mg/kg IV at a rate of 5 mg/kg per minute 3, 4
  • In clinical studies, levetiracetam showed a 73% response rate in patients with status epilepticus at this dose 3

Administration Considerations

  • Levetiracetam can be taken with or without food 1
  • For patients unable to swallow tablets, oral solution is available 1
  • For IV administration in acute settings, administer at 5 mg/kg per minute 3

Efficacy Considerations

  • At 2000 mg/day, approximately 37% of adults achieve a ≥50% reduction in seizure frequency compared to 8% with placebo 2
  • Clinical trials have shown that levetiracetam is effective as adjunctive therapy for partial onset seizures at doses of 1000,2000, and 3000 mg/day 5
  • The Number Needed to Treat for an additional beneficial outcome is approximately 5 for adults and 4 for children 2

Monitoring and Adverse Effects

  • Most common adverse effects include somnolence, asthenia, headache, and dizziness 5
  • In adults, somnolence (RR 1.51) and infection (RR 1.76) are significantly associated with levetiracetam 2
  • In children, behavioral changes may occur in up to 23% of patients 2
  • No clinically relevant interactions with other anticonvulsants, digoxin, warfarin, or oral contraceptives 5

Levetiracetam's favorable tolerability profile and low potential for drug interactions make it a valuable option for seizure treatment, though dosage should be adjusted based on clinical response and tolerability.

References

Research

Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review.

The Cochrane database of systematic reviews, 2012

Guideline

Treatment of Periodic Lateralized Epileptiform Discharges (PLEDs)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.